NEW RAPID MOLECULAR TEST FOR TUBERCULOSIS CAN SIMULTANEOUSLY DETECT
RESISTANCE TO FIRST- AND SECOND-LINE DRUGS

• Xpert® MTB/XDR cartridge enables expanded drug-resistance profiling in less than 90 minutes
• Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), the test could help fill a critical gap that is currently jeopardizing global TB targets

Geneva, Switzerland & Sunnyvale, CA, USA – 16 July 2020 – The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, announced today the launch of the new Xpert® MTB/XDR* test, which enables expanded drug-resistance tuberculosis (TB) profiling in less than 90 minutes. Xpert MTB/XDR can be used to empower clinicians to quickly prescribe treatment regimens for extensively drug-resistant TB (XDR-TB).

Able to detect TB that is resistant to multiple first- and second-line TB drugs, the test could help fill a critical gap that is currently jeopardizing global TB elimination targets. By contrast, current methods for identifying drug-resistance profiles for XDR-TB are very complex to perform, can take up to 16 weeks to deliver results, and as a result are often completely unavailable to patients.1

XDR-TB is the most complicated form of TB, with the worst outcomes. Mortality has been reported as high as 41% in some cohorts.2 The scientific community has been focused on coordinating innovation to improve both diagnosis and treatment of XDR-TB for years.3,4 The World Health Organization (WHO) recommends rapid molecular testing and detection of drug-resistant TB as an essential condition for the implementation of new treatment regimens.5

“An ordinary TB diagnosis is awful, but XDR-TB is the worst nightmare of every TB doctor and every patient,” said Catharina Boehme, CEO of FIND. “Recent treatment advances are already making a huge impact, but for the best chances of survival, patients need to be able to start on treatment as soon as possible – and the only way for that to happen is through rapid diagnosis. By providing test results in just a few hours, the Xpert MTB/XDR test will save lives.”

Xpert MTB/XDR leverages Cepheid’s new 10-colour technology, which enables the detection of multiple mutations across several genes, from a single sample. Xpert MTB/XDR can detect resistance to isoniazid, ethionamide, fluoroquinolones, amikacin, kanamycin and capreomycin. Access to testing that can reliably
identify resistance towards isoniazid as well as to fluoroquinolones and amikacin will help enable clinicians to quickly select the most appropriate MDR-TB treatment for each individual patient.6

“Rapid testing of resistance to isoniazid and fluoroquinolones is a critical step towards ensuring those who are ill with drug-resistant TB, and in particular XDR-TB, can access treatment and care early – in line with the latest WHO guidelines on the treatment of drug-resistant TB,” said Tereza Kasaeva, Director of the WHO Global TB Programme. “WHO is looking forward to receiving all relevant data on the GeneXpert MTB/XDR cartridge from Cepheid and partners to rapidly proceed with an evaluation of the new test.”

The test runs on Cepheid GeneXpert® systems equipped with 10-colour multiplexing modules. GeneXpert 10-colour modules are capable of processing the already widely used Xpert MTB/RIF and Xpert MTB/RIF Ultra* tests for diagnosis of TB and rifampicin resistance.

“This test is the first to leverage 10-colour homogeneous detection within the GeneXpert system,” said Dr David H Persing, Executive Vice President and Chief Medical and Technology Officer at Cepheid. “In partnership with Dr David Alland and his team at Rutgers University as well as FIND, we have demonstrated the ability to detect a wide array of TB drug resistance mutations directly from clinical specimens with a high level of accuracy comparable with standard testing.”

A study conducted by Cepheid showed promising results for the detection of mutations associated with first- and second-line drug resistance, while preliminary data from independent analytical and clinical evaluation studies conducted by FIND indicate that the test’s sensitivity (ability to correctly identify drug-resistance) and specificity (ability to correctly identify drug-susceptibility) is comparable with current standard tests (culture-based phenotypic drug-susceptibility testing) and sequencing, and that the test meets the performance characteristics defined by the high-priority target product profiles for new TB diagnostics.7

Data from the FIND evaluations will form part of the dossier now being prepared for WHO review at the end of this year. If the test is recommended for use by WHO, countries could include it in their national policies and accelerate its scale up – particularly in high-burden TB countries such as India and China.

“Reflex testing of MDR-TB patients, to rapidly and accurately diagnose XDR-TB within 2 hours and minimum expertise needed, has the potential to be the cornerstone in the rapid initiation of tailored treatment,” said Camilla Rodrigues, Consultant Microbiologist, Chairperson Infection Control Committee, P.D. Hinduja Hospital, Mumbai.

“It is great to have the Xpert MTB/XDR test that can be deployed in the peripheral laboratories and greatly improve access to diagnosis of drug-resistant TB and selection of the most appropriate treatment regimens,” said Lucica Ditiu, Executive Director of the Stop TB Partnership. “We should all work together to ensure that this and any other new TB diagnostics are fast-tracked from development, to WHO recommendation, to scale up and use by countries.”

FIND is now working with Cepheid and WHO to support the rollout of the test.

# # #
About FIND
FIND is a global non-profit organization that drives innovation in the development and delivery of diagnostics to combat major
diseases affecting the world's poorest populations. Our work bridges R&D to access, overcoming scientific barriers to technology
development; generating evidence for regulators and policy-makers; addressing market failures; and enabling accelerated uptake
and access to diagnostics in low- and middle-income countries (LMICs). Since 2003, we have been instrumental in the
development of 24 new diagnostic tools used in 150 LMICs. Over 50 million FIND-supported products have been provided to our
target markets since the start of 2015. A WHO Collaborating Centre, we work with more than 200 academic, industry,
governmental, and civil society partners worldwide, on over 70 active projects that cross six priority disease areas. FIND is
committed to a future in which diagnostics underpin treatment decisions and provide the foundation for disease surveillance,
control and prevention. For more information, please visit www.finddx.org

About Cepheid
Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher
Corporation's (NYSE: DHR) Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing,
and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual
procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic
testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on
those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and
cancer. For more information, visit http://www.cepheid.com.

Media contacts
FIND: Sarah-Jane Loveday, Head of Communications
+41 (0) 79 431 62 44
media@finddx.org

Cepheid Media Inquiries:
Darwa Peterson
darwa.peterson@cepheid.com

faq/en/ accessed May 2020